4//SEC Filing
Daniell Richard 4
Accession 0000950170-25-034607
CIK 0000818686other
Filed
Mar 5, 7:00 PM ET
Accepted
Mar 6, 4:06 PM ET
Size
24.8 KB
Accession
0000950170-25-034607
Insider Transaction Report
Form 4
Daniell Richard
Exec. VP, European Commercial
Transactions
- Sale
Ordinary Shares
2025-03-04$15.73/sh−21,870$344,116→ 11,641 total - Exercise/Conversion
Ordinary Shares
2025-03-04+183,169→ 183,169 total - Sale
Ordinary Shares
2025-03-04$15.73/sh−56,385$887,195→ 126,784 total - Sale
Ordinary Shares
2025-03-05$15.91/sh−30,015$477,635→ 96,769 total - Exercise/Conversion
Restricted Share Units
2025-03-04−33,512→ 33,512 total→ Ordinary Shares (33,512 underlying) - Exercise/Conversion
Restricted Share Units
2025-03-04−20,461→ 61,384 total→ Ordinary Shares (20,461 underlying) - Exercise/Conversion
Restricted Share Units
2025-03-04−183,169→ 0 total→ Ordinary Shares (183,169 underlying) - Exercise/Conversion
Ordinary Shares
2025-03-04+33,512→ 33,512 total - Sale
Ordinary Shares
2025-03-05$15.91/sh−11,641$185,246→ 0 total - Exercise/Conversion
Ordinary Shares
2025-03-04+20,461→ 20,461 total - Sale
Ordinary Shares
2025-03-04$15.73/sh−13,353$210,104→ 7,108 total - Sale
Ordinary Shares
2025-03-05$15.91/sh−7,108$113,111→ 0 total
Footnotes (9)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- [F3]The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2024.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.28 to $16.015, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.68 to $16.13, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F6]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
- [F7]Restricted share units were granted on March 4, 2022, with 33,512 vested on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 33,512 vesting on March 4, 2026.
- [F8]Restricted share units were granted on March 4, 2024, with 20,461 vested on March 4, 2025, 20,461 vesting on each of March 4, 2026 and March 4, 2027, and 20,462 vesting on March 4, 2028.
- [F9]Restricted share units were granted on January 28, 2025 pursuant to the satisfaction of performance criteria and vested on March 4, 2025.
Documents
Issuer
TEVA PHARMACEUTICAL INDUSTRIES LTD
CIK 0000818686
Entity typeother
Related Parties
1- filerCIK 0001726096
Filing Metadata
- Form type
- 4
- Filed
- Mar 5, 7:00 PM ET
- Accepted
- Mar 6, 4:06 PM ET
- Size
- 24.8 KB